Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Suid alphaherpesvirus 1 (SuHV-1), commonly known as Pseudorabies virus (PRV), is a linear double-stranded DNA virus belonging to the Alphaherpesvirinae subfamily of the Herpesviridae family [1, 3, 5]. It is the etiological agent of Aujeszky's disease, a highly contagious infection that primarily affects swine, leading to significant economic losses due to reproductive failure in sows, respiratory distress, and fatal neurological symptoms in piglets [1, 14]. Although pigs are the only natural reservoir, the virus exhibits a broad host range, infecting various mammals including cattle, sheep, dogs, and cats, where it typically causes a fatal "mad itch" (pruritus) and encephalitis [3, 14]. Recent reports have also highlighted its zoonotic potential, with cases of human encephalitis and endophthalmitis linked to PRV infection [4, 14]. PRV is characterized by its ability to establish lifelong latent infections in the peripheral nervous system, from which it can reactivate under stress [1, 12]. While there are no widely approved specific antiviral drugs for PRV in veterinary medicine, research has explored the use of DNA polymerase inhibitors like acyclovir and natural compounds such as germacrone and kaempferol to restrict viral replication [5, 6, 13].
Inhibition of viral DNA polymerase; Inhibition of immediate-early gene expression; Inhibition of viral attachment and entry; Modulation of host-virus interaction pathways (e.g., ANXA2 and Src kinase pathways)
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Suid alphaherpesvirus 1 (SuHV-1) (SuHV-1).